About GeoVax

GeoVax is a clinical-stage biotech company committed to developing safe and effective vaccines and immunotherapies against cancers and infectious diseases.

Our development programs are based upon a novel platform that integrates our recombinant Modified Vaccinia Ankara (MVA) vector technology with advanced antigen design and state-of-the-art manufacturing technologies. Vaccines produced in this platform are safe, highly immunogenic, suitable for repeated use, stable at refrigerator temperatures, can be lyophilized, and are amenable to rapid and affordable scale-up for use in both epidemic response and routine vaccination.
[Read more about our technology]

Our technology offers a “Plug and Play” platform approach that is well suited for use against a wide range of cancers and infectious diseases. Our HIV vaccine program is advancing in human clinical trials and our other programs in immuno-oncology and infectious diseases are at various stages of preclinical testing and discovery.
[See our product pipeline]

Our business strategy is to advance our products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also engage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.
[Read more about our collaborations]
Register to receive email alerts for GeoVax press releases
Copyright © GeoVax 2021. All Rights Reserved.